Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > volume today

<< Previous

Bullboard Posts

Next >>

Comment by Buylowerthanmoson May 10, 2019 1:03pm

68 Views

Post# 29734906

RE:RE:RE:RE:volume today

Im not an investor... I I I suspect this VIR has room to fall, ya he's a slouch I have no reason whatsoever to think otherwise. Perhaps VIR should have started trading at 43 cents current price as opposed to the $2.00 they launched on - that was a very SLOUCH move IMO.
I believe between now and shortly after the AGM this stock will contine to fail...or going in the downward DOG pose. I will wait for VIR to sink to the .25-30 cent range to consider...but probably not cuz i just dont have the faith that some like you do. This company does not have the average investor in mind.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading